Valeant Pharmaceuticals is drawing attention to a potential glaucoma treatment and its focus on product development, as the Canadian drugmaker continues to build its case to investors for a takeover of Botox-maker Allergan. [...] Valeant Chairman and CEO Michael Pearson said Thursday that his company is committed to health care innovation and funding important research. Valeant said the potential glaucoma drug, Vesneo, lowered eye pressure in late-stage research on patients with glaucoma or ocular hypertension.
Similar Stories to Valeant Pitches Potential Eye Drug, Research Focus on Bing News
By TOM MURPHY, AP Business Writer, Seattle Post-Intelligencer: Business
Thu, 09/25/2014 - 5:20am
Welcome to Wopular
Wopular is an
online newspaper rack,
giving you a summary view of the top headlines from the top news sites.
Senh Duong (Founder)
Wopular,
MWB,
RottenTomatoes
MoviesWithButter : Our Sister Site
- "Expendables 4" Starts Shooting This Fall, Says Randy Couture at the Arnold Sports Festival more
- “Expendables 4” Gets Funding Interest from “Ip Man 3” Financier more
- "Ip Man 3" Distributor Suspected of Box Office Fraud, Parent Company Loses $200M in Market Cap more
- Yen Targets "Ip Man 4" for 2018 Release; Discusses Film with Director, Producer more
- "Ip Man 3" Shatters Expectations with $72M Opening [China Box Office] more